Literature DB >> 17261644

Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion.

Holger Stepan1, Angela Unversucht, Niels Wessel, Renaldo Faber.   

Abstract

Angiogenic factors like placental growth factor and its antiangiogenic antagonist soluble fms-like tyrosine kinase 1 (sFlt1) are closely related to the pathogenesis of preeclampsia and intrauterine growth restriction. Because it is known that altered maternal sFlt1 and placental growth factor levels are detectable weeks before the onset of these pregnancy complications, it was the aim of the study to investigate the predictive value of these markers in high-risk second trimester pregnancies characterized by abnormal uterine perfusion. This prospective study includes 63 second trimester pregnant women with abnormal uterine perfusion. Twenty five of them developed a later complication (12 with preeclampsia, 11 with intrauterine growth restriction, and 2 with intrauterine death), whereas 38 had a normal course of pregnancy. Pregnancies with adverse pregnancy outcome showed in the second trimester significantly higher sFlt1 (1403.6+/-555 versus 451.8+/-42 pg/mL; P<0.05) and lower placental growth factor (139.6+/-24 versus 184.1+/-21 pg/mL) levels compared with those with normal outcome. These alterations were more pronounced in pregnancies with subsequent preeclampsia compared with intrauterine growth restriction and early onset diseases (delivery <34 weeks) compared with late-onset diseases. The combination of Doppler and sFlt1 increases the sensitivity of Doppler alone for iatrogenic preterm delivery from 64% up to 79% and the specificity from 63% up to 80%. Using both factors, sFlt1 and placental growth factor, early onset preeclampsia can be predicted with 83% sensitivity and 95% specificity. We conclude that the concurrent measurement of uterine perfusion and angiogenic factors allows an efficient prediction of early onset pregnancy complications, particularly preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261644     DOI: 10.1161/01.HYP.0000258404.21552.a3

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  46 in total

1.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 2.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

Review 3.  Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.

Authors:  Roberto Romero; Offer Erez; Maik Hüttemann; Eli Maymon; Bogdan Panaitescu; Agustin Conde-Agudelo; Percy Pacora; Bo Hyun Yoon; Lawrence I Grossman
Journal:  Am J Obstet Gynecol       Date:  2017-06-12       Impact factor: 8.661

4.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

5.  Placental Nkx2-5 and target gene expression in early-onset and severe preeclampsia.

Authors:  Elena R Rivers; Anthony J Horton; Angela F Hawk; Elizabeth G Favre; Katherine M Senf; Paul J Nietert; Eugene Y Chang; Ann C Foley; Christopher J Robinson; Kyu-Ho Lee
Journal:  Hypertens Pregnancy       Date:  2014-07-02       Impact factor: 2.108

6.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

7.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

8.  Combination of serum angiopoietin-2 and uterine artery Doppler for prediction of preeclampsia.

Authors:  Ploynin Puttapitakpong; Vorapong Phupong
Journal:  Hypertens Res       Date:  2015-10-22       Impact factor: 3.872

Review 9.  Morphological changes of placental syncytium and their implications for the pathogenesis of preeclampsia.

Authors:  Cynthia S Roland; Jian Hu; Chun-E Ren; Haibin Chen; Jinping Li; Megan S Varvoutis; Lynn W Leaphart; David B Byck; Xueqiong Zhu; Shi-Wen Jiang
Journal:  Cell Mol Life Sci       Date:  2015-10-26       Impact factor: 9.261

10.  The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome.

Authors:  Wiebke Schaarschmidt; Sarosh Rana; Holger Stepan
Journal:  J Perinat Med       Date:  2013-09-01       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.